Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus Letrozole or Anastrozole in First-line Advanced HR+/HER2- Breast Cancer
NCT03966898Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib in Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+), sponsored by Hengrui. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+)
Beyond the preview
Go deeper on NCT03966898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966898.